private:akrivis-2
|
658747
|
May 22nd, 2019 12:00AM
|
Akrivis Technologies, LLC
|
170
|
4.00
|
Open
|
Biotechnology
|
May 21st, 2019 09:20PM
|
May 21st, 2019 09:20PM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
Open
|
|
Open
|
One Broadway, 14th Floor
|
Cambridge
|
MA
|
US
|
02142
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Mar 18th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
151
|
9.00
|
Open
|
Biotechnology
|
Mar 18th, 2018 03:01PM
|
Mar 18th, 2018 03:01PM
|
|
Open
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 17th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 16th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 15th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 14th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 13th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 12th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 11th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|
private:akrivis-2
|
658747
|
Feb 10th, 2018 12:00AM
|
Akrivis Technologies, LLC
|
141
|
9.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases.
Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles).
In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.
|
|
|
|
|
|
|
|
|
|
Akrivis
|
|
Health Care Equipment & Services
|